Neelima Denduluri MD, Associate Professor, US Oncology Research, Virginia Cancer Specialists shares the results of the phase III EMBARCA trial that compares the efficacy and safety of talazoparib (TALA) to PCT (capecitabine, eribulin, gemcitabine, vinorelbine) in HER2-metastatic breast cancer patients.
